Exact slides after Cologuard volume disappoints

Exact Sciences Corp. (NASDAQ:EXAS) sank $12.62 (21%) to $46.50 in after-hours trading Aug. 1 after reporting a smaller-than-expected volume of completed Cologuard tests in its 2Q18 earnings. Cologuard is a non-invasive stool DNA test for colorectal cancer.

During the quarter, the volume of Cologuard tests grew 59% to 215,000 from 135,000 in 2Q17, but fell short of a 225,100 consensus estimate...